Technical Note

Development of repeatable microcatheter access port for intraarterial therapy of liver cancer

Yasushi Fukuoka MS⁽¹⁾, Toshihiro Tanaka MD, PhD⁽¹⁾, Hideyuki Nishiofuku MD, PhD⁽¹⁾, Takeshi Sato MD⁽¹⁾, Tetsuya Masada MD⁽¹⁾, Shota Tatsumoto MD⁽¹⁾, Nagaaki Marugami MD, PhD⁽¹⁾, Hiroshi Sakaguchi MD PhD⁽²⁾, Kimihiko Kichikawa MD, PhD⁽¹⁾

(1) Dept. of Radiology, Nara Medical University, Kashihara, Japan

(2) Dept. of Radiology, Minaminara Medical Center, Oyodo, Japan

Correspondence to: Toshihiro Tanaka, MD, PhD Department of Radiology, Nara Medical University 840 Shijo-cho, Kashihara, 634-8522, Japan Tel: +81-744-29-8900, Fax: +81-744-24-1988 E-mail: toshihir@bf6.so-net.ne.jp

Acknowledgment:

We thank Dr. Shunsuke Shimamura and Dr. Terumasa Shimada, Veterinary Medical Center, Osaka Prefecture University for support in this animal study. We thank Ms. Marian Pahud for advice in submitting this article. This work was supported by Grant-in-Aid for Scientific Research (C), 15K09967.

Key words,

Transarterial chemoembolization, Hepatic arterial infusion chemotherapy, Implantable port

Short Title,

Repeatable microcatheter access port

 \overline{a}

)
3
3
3

 $\mathbf{1}$ 2

3

4

5

6

Purpose

6

7

7

7

To develo

9

0

of repeate Purpose To develop an implantable port in which a microcatheter can be inserted for a combination therapy 1 O of repeated transarterial chemoembolization (TACE) and hepatic arterial infusion chemotherapy (HAIC) for advanced liver cancer. Materials and Methods The design of a currently used implantable port was modified. A funnel part was constructed in the port. The septum was punctured by a 20-gauge indwelling needle and 2.0 -Fr non-tapered microcatheter was inserted into the port. In in vitro studies, the extraction of the microcatheter $2\,4$ from the port through the funnel part was evaluated. A 5-Fr indwelling catheter connected to the port was placed in a vascular model and a microcatheter catherization was evaluated. In an in vivo study, the port-catheter system was implanted in the hepatic artery in a pig. A microcatheter was percutaneously inserted through the port into the hepatic arterial branches. Results In the in vitro studies, the microcatheter was smoothly extracted through the port and catheterizations into the hepatic arteries were successful via all 7 different septum puncture sites. In the in vivo study, repeated selective TACE through the port was successfully conducted on 7, 14 and 21 days after the implantation. $4\,4$ Conclusion The developed implantable port can be used for repeated catheter insertion into the hepatic artery. The combination of repeated TACE and HAIC could be possible using this device.

Introduction

There are various treatment options in intraarterial therapy for advanced liver cancer [1,2]. Transarterial chemoembolization (TACE) using drug eluting microspheres is widely performed in liver metastases, i.e. colorectal cancer (mCRC) [3,4). Hepatic arterial infusion chemotherapy $(HAIC)$ is also an effective treatment for mCRC [5-7].

In general, for advanced liver cancers, repeated TACE is required. Previous reports showed that TACE using irinotecan eluting microspheres are performed 2 to 5 times in mCRC patients [8]. Longer repeated TACE period could improve the overall survival duration [9]. Therefore, smaller or biodegradable microspheres have been innovated to improve the repeatability of TACE $[10-15]$.

After achieving a tumor response using TACE, effective maintenance chemotherapy is required. Alternative treatments of TACE and chemotherapies may also be effective. However, many patients who are receiving TACE have already been refractory to standard systemic chemotherapies $[16, 17]$. In such a situation, HAIC might be promising to suppress tumor regrowth after TACE.

To perform combination treatments of repeated TACE and HAIC, a repeatable microcatheter access port was developed. Herein the in vitro and in vivo experimental results using this device are shown.

Materials and Methods

Concept and development of repeatable microcatheter access port

The design of a currently used port was modified. This developed port was constructed in three parts, a body, a funnel and a cap. A silicon septum was inserted into the cap part. The diameter of the septum was set 15mm for a needle to easily puncture the septum. The slope of the funnel was set at a 60° angle for a microcatheter to smoothly slide along the funnel wall to the bottom (Fig 1). The surface of an inner lumen of the funnel part was carefully polished to prevent stack of a microcatheter by a polish machine (SMAP, Toyo Kenmazai Kogyo Ltd., Tokyo, Japan). A 20-gauge indwelling needle consisting of an inner needle and outer cylinder needle was used for the puncture of the septum of the port allowing for a 2.0-Fr microcatheter to be inserted.

In vitro evaluation

Firstly, extraction of a microcatheter through the port was tested. A total of 7 puncture sites were selected on the septum, center, and 2mm and 4mm concentrically from the center (Fig 2). The septum was punctured vertically by a 20-gauge indwelling needle (Surflo; Terumo, Tokyo, Japan). After removal of the inner needle, a commercially available 2.0-Fr non-tapered microcatheter (Carnelian Marvel, Tokay Medical Product, Kasugai, Japan) with an 0.014-inch guidewire (GT wire, Terumo) was inserted into the port. The success rate of the microcatheter with a guide wire which was passed through the funnel part and extracted from the port was evaluated.

Secondly, a 5-Fr catheter with a side hole was placed in a vascular model. The tip of the catheter was inserted into the gastroduodenal artery and the side hole was positioned in the common hepatic artery. The proximal end of the catheter was connected to the developed port. A microcatheter was inserted into the port at each of the 7 puncture sites and the tip of the microcatheter was ejected from the side hole. Then, the microcatheter was inserted into the right and left hepatic arteries (Fig 3). The success rate of the selective insertion of the microcatheter into the hepatic arterial branch was evaluated.

s In vivo evaluation

3 The study was performed at Veterinary Medical Center, Osaka Prefecture University, Japan. The study protocol was approved by the State Committee of Osaka Prefecture University. One pig weighing 55 kg was used. After intramuscular premedication atropine and ketamine, anesthesia was induced by intravenous injection of diluted pentobarbital. The animal was orotracheally intubated and mechanically ventilated with an oxygen-air mixture containing halothane.

> The right iliac artery was exposed via a surgical cut-down and a 4-Fr sheath (Hanako Medical, Tokyo, Japan) was introduced. A 4-Fr cobra-shaped angiographic catheter (Hanako Medical) was inserted into the celiac trunk, and a celiac angiogram was obtained. A $2.5\text{-}Fr$, 105-cm-long microcatheter (Renegade, Boston Scientific, Marlborough, USA) was inserted into the gastroduodenal artery. A 0.018-inch, 205-cm stiff guide wire (Rainbow, Piolax Medical Devices, Yokohama, Japan) was inserted through the microcatheter. Then, the whole system, including the sheath, the angiographic catheter, and the microcatheter, was replaced by an anticoagulant-coated indwelling catheter, with a 5-Fr proximal shaft and a 2.7-Fr distal shaft (Anthron PU catheter, Toray Medical, Urawa, Japan). A side hole approximately 3mm in size was created with scissor cut at the transition zone from the shaft to the tapered tip. The catheter tip was inserted into the distal gastroduodenal artery and the side hole was positioned at the common hepatic artery. A 2.5-Fr microcatheter was inserted into the gastroduodenal artery through the side-hole and microcoils (Tornado; Cook, Bloomington, USA) were placed to fix the indwelling catheter. Finally, at the right inguinal region, a U-shaped subcutaneous tunnel was created up from the iliac arterial puncture site. The proximal end of the catheter was connected to the developed port embedded under the skin.

After the implantation of the port-catheter system, the port was punctured percutaneously by a 20-gauge needle, and a 2.0-Fr non-tapered microcatheter with a 0.014 -inch guidewire was

introduced into the port. The microcatheter was inserted into the hepatic arterial branch in a 45686569 segmental level selectively and lipiodol emulsion was injected. Repeated TACE was performed
 $\frac{7}{8}$ every week for 3 weeks.
 $\frac{9}{10}$

11 every week for 3 weeks.

Results

Accessibility of a microcatheter through the port

In the first part of the in vitro study, the microcatheter was extracted through the funnel part via all 7 puncture sites. In the second part, in all 7 puncture sites, the microcatheter was ejected via the side hole and was inserted into the left and right hepatic arteries of the vascular model.

Feasibility of selective TACE through the port

The catheter-port system was successfully placed into the pig. On day 7 after the port-catheter system implantation, the pig was carried to the angio-room and a hepatic arteriography was obtained via the port (Fig 4). Then, a rnicrocatheter was inserted percutaneously through the port. The tip of the microcatheter was extracted through the side-hole and selectively inserted into the left hepatic artery. During the catherization procedure, no bleeding occurred beside the inserted microcatheter. Embolization with an emulsion of lipiodol 4mL and contrast material 2mL was performed in the left lateral segment. After the TACE procedure, the microcatheter was removed and heparin at a dose of 2.5 mL was injected in the port-catheter system. The pig was moved to a CT room and a CT scan was obtained to confirm the embolization area. This procedure was successfully repeated. The right anterior and middle hepatic arteries were embolized on days 14 and 21, respectively (Fig 5).

Discussion

 $\mathbf{1}$

Previously, Itano et al. reported their development of a microcatheter accessible system, Systemi, in which a latex rubber cap was connected to an indwelling 5-Fr catheter and subcutaneously implanted [18]. In their system, the rubber cap had to be punctured for the microcatheter insertion, which was technically quite difficult because the puncture target was a small size and the puncture direction was parallel to the skin. To overcome the difficulty of the puncture, the shape and design of our device was modified based on currently used central venous or arterial ports. The top of the port can be easily punctured vertically to the skin. The septum with l 5mm in diameter also allowed a needle to blindly hit.

In the construction of this port, the shape of the funnel part was paramount. A microcatheter inserted through the septum must be extracted smoothly from the port. The peripheral puncture site in the septum could make it be difficult. However, the extraction of a microcatheter w successful via every puncture site. The funnel with a standard angel of 60° could be optimal for a micocatheter to slide to the bottom. The 18mm height of the port was based on the ratio of the diameter of the septum to the angle of the funnel. This height could be acceptable for subcutaneous implantation.

The in vitro study showed the feasibility of the repeated selective TACE. The microcatheter was successfully inserted via the port and selective catheterization was performed every week for 3 weeks. No bleeding occurred through the needle puncture site. The system was not obstructed during the observation period. In this pig study, the iliac artery was exposed via a surgical cutdown to prevent kinking of the catheter due to any leg movement. In clinical practice, percutaneous catheter insertion technique was established without any difficulties in HAIC using the port-catheter system.

The concept of this device is to perform repeated TACE and also to perform HAIC. Intermittent tumor volume reduction could be achieved by the repeated selective or non-selective TACE and maintenance therapy by HAIC could suppress tumor regrowth. The efficacy of this combination must be evaluated in clinical studies.

When HAIC is performed in patients with anatomical variations of the hepatic artery, i.e. the replaced right arising from the superior mesenteric artery, the proximal site of the replaced hepatic artery is embolized with coils and a single port-catheter is placed in the main hepatic artery [19,20]. However, after the embolization, a microcatheter cannot be inserted into the replaced hepatic artery. Therefore, in the combination of TACE and HAIC using the developed port, two port-catheter systems must be placed in both hepatic arteries.

There are several limitations in this study. Firstly, the in vivo study was performed using only one pig. Secondly, we used a normal puncture needle. Before clinical use of this system, development of a Huber needle with an outer cylinder is essential. Thirdly, the tolerability of the silicon septum by multiple punctures using a 20-gauge needle must be checked.

In conclusion, a microcatheter access port was developed and the feasibility of repeated microcatheter insertion was shown in an in vitro and in vivo study. The combination of repeated TACE and HAIC for liver tumors could be possible using this device.

Conflict of Interest Statement

All authors have no conflicts of interest and financial disclosures to declare.

Ethical Approval Statement

All applicable institutional and national guidelines for the care and use of animals were followed.

Informed Consent Statement

 $1\,$ \overline{c} $\overline{4}$ 3 Does not apply.

Figure Legends

Fig 1

Design and picture of the port

The diameter of the septum is 15mm. The slope of the funnel is 60° angle. The height of the port

is 18mm.

Fig2

First part of the in vitro study

A total of 7 puncture sites were selected on the septum, center, and 2mm and 4mm concentrically from the center. The septum was punctured vertically by a 20-gauge indwelling needle and a microcatheter was inserted through the needle.

Fig3

The second part of the in vitro study using a vascular model

A 5-Fr indwelling catheter was placed in the vascular model. The catheter tip was inserted into the gastroduodenal artery (arrow) and the side hole was positioned at the common hepatic artery (arrowhead). A microcatheter with a guidewire was inserted into the hepatic artery through the indwelling port-catheter system.

Hepatic arteriography via the port

ASFrindwelling catheter was placed in the vascular model. The catheter tip was inserted into the gastroduodenal artery (arrow) and the side hole was positioned at the common hepatic artery (arrowhead).

Fig 5

Selective arteriography and CT after injection of lipiodol emulsion

Amicrocatheter was inserted into the left hepatic artery on day 7 (top), the right anterior hepatic

artery on day 14 (middle) and the middle hepatic artery on day 21 (bottom).

3 References

- (1) Mahnken AH, Pereira PL, de Baère T. Interventional oncologic approaches to liver metastases. Radiology. 2013;266(2):407-30.
- (2) Wang DS, Louie JD, Sze DY. Intra-arterial therapies for metastatic colorectal cancer. Semin Intervent Radiol. 2013 Mar;30(1):12-20.
- (3) Young S, D'Souza D, Flanagan S, Golzarian J. Review of the Clinical Evidence for the Use of DEBIRI in the Treatment of Colorectal Metastatic Disease. Cardiovasc Intervent Radiol. 2017;40(4):496-501.
- (4) Richardson AJ, Laurence JM, Lam VW. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review. J Vasc Interv Radiol. 2013;24(8):1209-17.
- (5) Arai Y, Ohtsu A, Sato Y, et al. Phase I/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI. J Vasc Interv Radiol. 2012;23(10):12617.
- (6) Nishiofuku H, Tanaka T, Aramaki T, et al. Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis. Clin Colorectal Cancer. 2010; 9:305 10.
- (7) Chapelle N, Matysiak-Budnik T, Douane F, Metairie S, Rougier P, Touchefeu Y. Hepatic arterial infusion in the management of colorectal cancer liver metastasis: Current and future perspectives. Dig Liver Dis. $2018;50(3):220-225$.

- (8) Lencioni R, Aliberti C, de Baere T, et al. Transarterial treatment of colorectal cancer liver metastases with irinotecan-loaded drug-eluting beads: technical recommendations. J Vasc Interv Radiol. 2014;25(3):365-9.
- (9) Akinwande OK, Philips P, Duras P, Pluntke S, Scoggins C, Martin RC. Small versus largesized drug-eluting beads (DEBIRI) for the treatment of hepatic colorectal metastases: a propensity score matching analysis. Cardiovasc Intervent Radiol. 2015;38(2):36171.
- (10) Mauri G, Varano GM, Della Vigna P, et al. Transarterial Embolization with Small-Size Particles Loaded with Irinotecan for the Treatment of Colorectal Liver Metastases: Results of the MIRACLE III Study. Cardiovasc Intervent Radiol. 2018 Jun 27. doi: 10.1007/s00270-018-2017-x.
- $(1$ Poursaid A, Jensen MM, Huo E, Ghandehari H. Polymeric materials for embolic and chemoembolic applications. J Control Release. 2016; 28(240):414-433.
- (12) Tanaka T, Nishiofuku H, Maeda S, et al. Repeated bland-TAE using small microspheres injected via an implantable port-catheter system for liver metastases: an initial experience. Cardiovasc Intervent Radiol. 2014; 37:493-7.
- (13) NishioikuH, Tanaka T, Matsuoka M, et al. Transcatheter arterial chemoembolization using cisplatin powder mixed with degradable starch microspheres for colorectal liver metastases after FOLFOX failure: results of a phase I/II study. J Vasc Interv Radiol. 2013; 24:56-65.
- (14) Tanaka T, Nishiofuku H, Hukuoka Y, et al. Pharmacokinetics and antitumor efficacy of chemoembolization using 40 μm irinotecan-loaded microspheres in a rabbit liver tumor model. J Vasc Interv Radiol. 2014;25(7):1037-44.

 $\mathbf{1}$

- (15) Sato T, Tanaka T, Nishiofuku H, et al. Pharmacokinetics and Histopathological Findings of Chemoembolization Using Cisplatin Powder Mixed with Degradable Starch Microspheres in a Rabbit Liver Tumor Model. Cardiovasc Intervent Radiol 2017;40(3):438 444.
- (16) Bhutiani N, Akinwande 0, Martin RC 2nd. Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases. World J Surg. 2016;40(5):1178-90.
- (17) Iezzi R, Marsico VA, Guerra A, et al. Cardiovasc Intervent Radiol. Trans-Arterial Chemoembolization with Irinotecan-Loaded Drug-Eluting Beads (DEBIRI) and Capecitabine in Refractory Liver Prevalent Colorectal Metastases: A Phase II Single-Center Study. Cardiovasc Intervent Radiol 2015;38(6):1523-31.
- (18) Itano 0, Itano S, Nagamatsu H, et al. Intermittent transcatheter therapy through a new indwelling catheter system for patients with hepatocellular carcinoma. Jpn J Radiol. 2014 Nov;32(11):670-5.
- (19) Arai Y, Takeuchi Y, Inaba Y, et al. Percutaneous catheter placement for hepatic arterial infusion chemotherapy. Tech Vasc Interventional Rad 2007; 10:30-7.
- $\frac{43}{44}$. (20) Tanaka T, Arai Y, Inaba Y, et al. Radiologic placement of side-hole catheter with tip 4 6 fixation for hepatic arterial infusion chemotherapy. J Vasc Interv Radiol 2003; 14:63-8. 47

 $1\,$

